Tag: Policy + Advocacy Updates

Act Today and Tell Your Member of Congress: Oppose Government Price Setting Congress is negotiating sweeping legislation that impacts life sciences. The current reconciliation bill includes language t...

Congress is negotiating sweeping legislation that impacts life sciences. Colorado BioScience Association (CBSA) remains active on these important legislative proposals, which include supporting the re...

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are vital for our life sciences community. They provide early non-dilutive funding to advance high-...

Democrats in the U.S. Senate continue to negotiate an economic package that advances President Joe Biden’s key priorities. Prescription drug pricing legislation that would drastically alter the Medica...

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are vital for our life sciences community. They provide early non-dilutive funding to help advance...

Earlier this month, Colorado BioScience Association (CBSA) partnered with Biotechnology Innovation Organization (BIO) and sent a letter to Congress urging immediate legislative action to repeal the ha...

Earlier this month, Colorado BioScience Association (CBSA) engaged on the U.S. Food and Drug Administration’s (FDA) Safety and Landmark Advancements (FDASLA) Act. CBSA and our national partners suppor...

Colorado BioScience Association (CBSA) and our national partners support the critically important reauthorization of the U.S. Food and Drug Administration’s (FDA) prescription drug, generic drug, bios...

A longstanding policy priority for CBSA is supporting our ecosystem’s need for increased access to capital. Through our Capital + Growth efforts, we work closely with public and private partners to ac...

The 2022 legislative session, the Second Regular Session of the 73rd General Assembly, has concluded. It was an unprecedented session that  began with the legislature having significant financial...